Cargando…
Pasireotide for the Medical Management of Feline Hypersomatotropism
BACKGROUND: Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST. HYPOTHESIS/OBJECTIVES: Pasireotide improves biochemical control of HST and diabetes mellitus in c...
Autores principales: | Scudder, C.J., Gostelow, R., Forcada, Y., Schmid, H.A., Church, D., Niessen, S.J.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895359/ https://www.ncbi.nlm.nih.gov/pubmed/25945588 http://dx.doi.org/10.1111/jvim.12608 |
Ejemplares similares
-
Pasireotide Long‐Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism
por: Gostelow, R., et al.
Publicado: (2017) -
Serum N‐Terminal Type III Procollagen Propeptide: An Indicator of Growth Hormone Excess and Response to Treatment in Feline Hypersomatotropism
por: Keyte, S.V., et al.
Publicado: (2016) -
Efficacy of hypophysectomy for the treatment of hypersomatotropism‐induced diabetes mellitus in 68 cats
por: Fenn, Joe, et al.
Publicado: (2021) -
Hypersomatotropism in 3 Cats without Concurrent Diabetes Mellitus
por: Fletcher, J.M., et al.
Publicado: (2016) -
Evaluation and Diagnostic Potential of Serum Ghrelin in Feline Hypersomatotropism and Diabetes Mellitus
por: Jensen, K.B., et al.
Publicado: (2015)